Overall, we believe that our findings have high clinical relevance since identify rs822336 and induction of PD-L1 expression as novel and efficient predictive biomarkers of tumor response to anti-PD-1/PD-L1 therapy in patients with advanced non-oncogene addicted NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.